On a crisp sunny day in late March, lawyers from 39 law firms gathered at the corporate headquarters of Pfizer Inc., a nondescript office building a couple of blocks east of Grand Central Station in New York. The collective mood was cheerful. After all, each of the firms still had a piece of Pfizer’s U.S. litigation work.
Two years earlier, the company had dumped 80 percent of its hundreds of outside counsel in a convergence project called P3, the Pfizer Partnering Program. Now, representatives from the survivors had been convened to receive an update.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
